Targeting IL-33 in patients with cancer under immune checkpoint inhibitors for a better antitumor response and prevent thromboembolism?

Targeting IL-33 in patients with cancer under immune checkpoint inhibitors for a better antitumor response and prevent thromboembolism?

Saved in:

Bibliographic Details
Main Authors:	Gianluca Azzellino, Lia Ginaldi, Massimo De Martinis
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-02-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/2/e010806.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01)

A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops
by: Ayaka Kawaguchi, et al.
Published: (2025-03-01)

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types
by: Jeanne Shen, et al.
Published: (2024-02-01)

Prognostic value of body adipose tissue parameters in cancer patients treated with immune checkpoint inhibitors
by: Yan Li, et al.
Published: (2025-02-01)

Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors
by: Philippe Rochigneux, et al.
Published: (2025-02-01)

Clinical outcomes after immune checkpoint inhibitor-associated acute kidney injury: a cohort study
by: Vin-Cent Wu, et al.
Published: (2025-02-01)

Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma
by: Maki Todo, et al.
Published: (2025-02-01)

Nomograms based on ratio indexes to predict severity and prognosis in immune checkpoint inhibitors-related myocarditis: a retrospective analysis
by: Zhenli Li, et al.
Published: (2024-05-01)

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study
by: Haiqing Zhao, et al.
Published: (2024-09-01)

Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports
by: Alessandro Ceschi, et al.
Published: (2019-05-01)

The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study
by: Keiichiro Suminaga, et al.
Published: (2025-02-01)

Differentially expressed microRNAs in pre-transplant lung biopsies target immune checkpoint proteins and can predict primary graft dysfunction in lung transplantation
by: Vitale Miceli, et al.
Published: (2025-02-01)

Author Correction: Influencing immunity: role of extracellular vesicles in tumor immune checkpoint dynamics
by: Ziyang Ye, et al.
Published: (2025-01-01)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
by: Xia Liu, et al.
Published: (2022-10-01)

Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
by: Michael Hoffmeister, et al.
Published: (2025-02-01)

Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer
by: Furnback W, et al.
Published: (2025-02-01)

Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
by: Xiuyue Man, et al.
Published: (2025-02-01)

Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
by: Jesse Haramati, et al.
Published: (2025-02-01)

Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune response
by: Jing Wang, et al.
Published: (2023-08-01)

Mutation of isocitrate dehydrogenase indicates favorable outcomes in pan-cancer immune checkpoint blockade
by: Zhiyang Huang, et al.
Published: (2025-02-01)

Mitochondria-targeted photothermal-chemodynamic therapy enhances checkpoint blockade immunotherapy on colon cancer
by: Benchao Zheng, et al.
Published: (2025-04-01)

Chapter 33: Parsley Production in Florida
by: George J. Hochmuth, et al.
Published: (2019-05-01)

Chapter 33: Parsley Production in Florida
by: George J. Hochmuth, et al.
Published: (2019-05-01)

Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade
by: Xiaolin Liu, et al.
Published: (2025-02-01)

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01)

The strange case of the patriarchs in Jeremaiah 33:26
by: C. Lombaard
Published: (2015-12-01)

Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade
by: Yo-Ting Tsai, et al.
Published: (2024-03-01)

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
by: Vivek Subbiah, et al.
Published: (2025-02-01)

Comment on: Multimorbidity, comorbidity, frailty, and venous thromboembolism
by: Maria I. Zervou, et al.
Published: (2025-02-01)

CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors
by: Chrystal Paulos, et al.
Published: (2025-02-01)

Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis
by: Lingling Zhao, et al.
Published: (2025-02-01)

DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells
by: Ignacio Melero, et al.
Published: (2021-05-01)

Response to Comment on: Multimorbidity, comorbidity, frailty, and venous thromboembolism
by: Bengt Zöller, et al.
Published: (2025-02-01)

T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
by: Linghua Wang, et al.
Published: (2023-08-01)

Causal relationship between educational attainment and the occurrence of venous thromboembolism
by: Sitong Guo, et al.
Published: (2025-02-01)

Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies
by: Wanli Zhang, et al.
Published: (2025-02-01)

Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts
by: Kelley Weinfurtner, et al.
Published: (2025-03-01)

Case Report: Dangerous liaisons between splenectomy and eltrombopag-induced chronic thromboembolic pulmonary hypertension in patients with immune thrombocytopenia: report of two cases and review of the literature
by: Roberto Castelli, et al.
Published: (2025-02-01)

In vitro antitumor and immunomodulatory activities of 1,2,4-oxadiazole derivatives
by: Héverton Mendes Araújo, et al.
Published: (2025-03-01)

Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastoma
by: Douglas A Lauffenburger, et al.
Published: (2025-02-01)